Compare RMCF & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMCF | HIND |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | United States |
| Employees | N/A | 18 |
| Industry | Specialty Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 15.2M |
| IPO Year | 2024 | 2016 |
| Metric | RMCF | HIND |
|---|---|---|
| Price | $0.88 | $2.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 135.5K | 18.5K |
| Earning Date | 06-16-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,432,352.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $1.75 |
| 52 Week High | $2.99 | $12.87 |
| Indicator | RMCF | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 18.91 | 47.34 |
| Support Level | N/A | $1.99 |
| Resistance Level | $1.87 | $2.39 |
| Average True Range (ATR) | 0.19 | 0.13 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 2.27 | 14.93 |
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The company prepares numerous products, including caramel apples in the store. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, and Others. The company derives maximum revenue through manufacturing activities. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.